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Summary 
Laboratory medicine and clinical medicine are co-dependent
components of medicine. Laboratory medicine functions
most effectively when focused through a clinical lens. Me dical
practice as a whole undergoes change. New drugs, treat-
ments and changes in management strategies are intro-
duced. New techniques, new technologies and new tests are
developed. These changes may be either clinically or labora-
tory initiated, and so their introduction requires dialogue and
interaction between clinical and laboratory medicine special-
ists. Treatment monitoring is integral to laboratory medicine,
varying from direct drug measurement to monitoring choles-
terol levels in response to treatment. The current trend to
»personalised medicine« is an extension of this process with
the development of companion diagnostics. Technological
innovation forms part of modern laboratory practice.
Introduction of new technology both facilitates standard lab-
oratory approaches and permits introduction of new tests and
testing strategies previously confined to the research labora-
tory only. The revolution in cardiac biomarker testing has
been largely a laboratory led change. Flexibility in service pro-
vision in response to changing clinical practice or evolving
technology provides a significant laboratory management
challenge in the light of increasing expectations, shifts in pop-
ulation demographics and constraint in resource availability.
Laboratory medicine practitioners are adept at meeting these
challenges. One thing remains constant, that there will be a
constant need laboratory medicine to meet the challenges of
novel clinical challenges from infectious diseases to medical
conditions developing from lifestyle and longevity.
Keywords: evidence based medicine, drug monitoring,
analytical methods, infection, cardiac biomarkers, point of
care testing 
Kratak sadr`aj
Laboratorijska medicina i klini~ka medicina su me|usobno
zavisne grane medicine. Laboratorijska medicina najefiksani-
je funkcioni{e ako deluje sa klini~kog stanovi{ta. Danas u
celini medicinska praksa se stalno menja. Uvode se novi
lekovi, postupci, kao {to se menja i upravlja~ka strategija.
Razvijaju se nove tehnike, nove tehnologije i novi testovi. Ove
promene su klini~ki ili laboratorijski inicirane, zbog ~ega nji-
hovo uvo|enje zahteva stalnu saradnju izme|u klini~kih i lab-
oratorijskih specijalista. Pra}enje tretmana pacijenata je inte-
gralni deo laboratorijske medicine, kao npr. preko direktnog
merenja leka do pra}enja nivoa holesterola kao odgovora na
tretman lekom. Sada{nji trend tzv. »personalizovane medi-
cine« je odgovor na ovaj proces uz razvoj odgovaraju}e dijag-
nostike. Tehnolo{ka unapre|enja uti~u na razvoj moderne
laboratorijske prakse. Uvo|enje novih tehnologija potpo-
ma`u standardni laboratorijski pristupi kao i uvo|enje novih
testova i strategije ispitivanja koja je predhodno potvr|ena u
istra`iva~kim laboratorijama. Tako je npr. revolucija u razvoju
sr~anih biomarkera dovela do veklih promena u laboratorij -
skoj praksi. Fleksibilnost u laboratorijskom sistemu una pre -
|uje klini~ku praksu i tehnologije koje dovode do zna~ajnih
promena u sistemu upravljanja laboratorijom, a zavisno od
o~ekivanja, demografskih promena i razvoja resursa. Zato
stru~njaci u oblasti laboratorijske mdicine moraju da budu
spremni da prihvate ove promene. Jedna ~injenica ostaje
konstantna, a to je da }e uvek biti stalna potreba za labora-
torijskom medicinom koja je spremna da prihvati klini~ke iza-
zove od infektivnih oboljenja do medicinskih stanja zavisno
od na~ina i du`ine `ivota.
Klju~ne re~i: medicina zasnovana na dokazima, pra}enje
lekova, analiti~ke metode, infekcija, sr~ani biomarkeri, ispiti-
vanje pored pacijenta (POCT)
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Introduction
Laboratory medicine and clinical medicine are
not separate entities. Both form part of the practice of
medicine as a whole. Clinical history and examination
produced a diagnostic hypothesis, usually expressed
as a differential diagnosis list. Subsequent investiga-
tions including laboratory testing act to refine the
diagnostic hypothesis towards a management plan. It
has been stated that laboratory testing directly affects
70% of the clinical decisions in the patient pathway.
Clinical patient assessment raises the prior probability
of disease so that when appropriate laboratory testing
is used, diagnostic sensitivity and specificity are
improved. Indiscriminate testing result in reduction of
the diagnostic efficiency of laboratory testing and is a
waste of valuable resource. Laboratory medical prac-
titioners therefore need to understand not just the
analytical components of testing but how and where
testing will be applied and what it will be used for.
However, an understanding of test utilisation includes
not just the clinical condition being investigated but
also the process of patient flow. Laboratory medical
practitioners should be laboratory based but outward
facing. Clinicians need to understand the strengths
and weaknesses of testing and also how this fits into
the decision-making process. They often have little
appreciation of those factors in analysis which labora-
tory medicine takes the granted, such as analytical
performance (detection limit and imprecision) and do
not consider where turnaround time may directly
improve patient pathways. Dialogue between labora-
tory medicine practitioners and clinicians and educa-
tion of each by the other is essential. Such a dialogue
will allow clinicians an understanding of the strengths
and weaknesses of testing and the laboratory com-
munity of where there is clinically unmet need (1, 2).
Medical practice undergoes a continuous pro-
cess of change. There are a number of different
drivers of change. There may be development of new
drugs, new treatments or changes in management
strategies. Introduction of new techniques, new tech-
nologies and new tests occurs on a regular basis.
Changing practice or external pressures may require
review of service configuration. Finally there is always
the challenge of meeting future needs. Laboratory
medicine has developed in parallel with medical prac-
tice. In some cases, medical practice will lead labora-
tory medicine development but equally laboratory
medicine can be the standard setter and the innova-
tion leader, developing to support or extend clinical
medical practice. 
Laboratory medicine, new drugs new
treatments and changes in management
strategies
Treatment monitoring may be direct, indirect or
target focussed. When drug treatments are devel-
oped and introduced there is typically a need for
direct laboratory medicine support. Drug monitoring
is developed for the majority of agents, initially by the
pharmaceutical company that introduces the new
drug. Such drug measurement is to enable them to
characterise the pharmacokinetics of their agent and
facilitate clinical trials. There may or may not then be
transition from the research to the clinical laboratory
depending on whether the drug requires therapeutic
drug monitoring (TDM). TDM for drugs is based on
the value proposition that standardised measurement
and interpretation has a direct impact on patient care.
Although the major application is in drugs with a rel-
atively narrow therapeutic range and clear toxic side-
effects there is also a role in compliance monitoring.
The role of the laboratory in TDM is central as knowl-
edge of the underlying pharmacokinetics of the drug
defines the ideal sampling strategies and optimal ana-
lytical techniques. Changes in laboratory methodolo-
gy can significantly improve both the analytical accu-
racy and availability of TDM. This is illustrated by the
transition from radioimmunoassay to non-isotopic
fully automated real-time immunoassay. Laboratory
medicine also has a significant role to play by applica-
tion of evidence-based medicine to show where TDM
is inappropriate. The laboratory also has a challenge
in addressing the recreational drugs area. Novel
agents are constantly being developed by ingenious
chemists and the challenge is to be able to detect
these agents in comatose individuals or where there
is evidence of unexplained neurological syndromes
subsequent to ingestion (3).
Direct treatment monitoring is well-established
as a part of laboratory medicine. Hormonal treatment
is entirely dependent on laboratory medicine.
Monitoring thyroxine dosage by measurement of thy-
roxine and thyroid-stimulating hormone is standard
clinical practice. Goal directed therapy is a more
recent innovation. The development of effective
cholesterol lowering therapy in the form of 3-hydroxy-
3-methyl-glutaryl-coenzyme A reductase inhibitors
(HMG CoA reductase inhibitors, statins) and subse-
quent clinical trials (4, 5) lead to acceptance of the
pivotal role of cholesterol lowering in treatment of
atheromatous coronary vascular disease (6). This
paradigm shift in management has resulted in the
routine measurement of cholesterol reduction in
response to statin therapy to achieve targets recom-
mended by clinical guidelines (7). Determination of
antibiotic resistance patterns rapidly became a crucial
part of infection management. As novel antibiotics
are introduced, resistance testing is required to mon-
itor emergence of resistance patterns. A crucial com-
ponent of antibiotic stewardship is the ability to avoid
treatment of nonbacterial infections with antibiotics,
to discontinue ineffective treatments and to limit
treatment duration. Laboratory real time measure-
ment of markers to help in the assessment of whether
sepsis is present and whether antibiotic therapy is
Unauthenticated
Download Date | 8/11/17 11:51 AM
J Med Biochem 2017; 36 (3) 213
being effective and can be discontinued has been
developed in response to this challenge (8, 9).
Specific diagnostic tests have been developed to tailor
individual treatments to individual patients, the con-
cept of »personalised medicine«. Tailored treatment is
most advanced in the area of cancer chemotherapy.
The recognition of specific subtypes of tumours due
to particular oncogene mutations has resulted in spe-
cific targeted therapies. The role of the laboratory is
to identify susceptible tumour types to target the use
of these novel (and often extremely expensive) thera-
pies. Examples include her-2 neu for herceptin thera-
py in breast cancer and Kras for Cetuximab for col-
orectal cancer (10).
Changes in clinical practice and management
pathways may also require changes in the laboratory.
An example is the recognition of the increasing inci-
dence of fatty liver either as non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis
(NASH) (11). These present to the hepatologist ini-
tially as a sustained elevation of alanine transaminase
(ALT). Standard management is to proceed to liver
biopsy if the diagnosis is unclear. However, liver biop-
sy is an invasive procedure with morbidity and mortal-
ity. Alternative strategies have been proposed to avoid
the need for liver biopsy by reintroduction of mea-
surement of aspartate transaminase (AST) and use of
the ALT/AST ratio as part of a management algo-
rithm (12).
Laboratory medicine, new techniques,
new technologies and new tests
Introduction of new techniques and new tech-
nology has always been part of the core role of labo-
ratory medicine. The transition from manual tech-
niques to early automation such as the autoanalyser
and now to fully integrated robotic computerised sys-
tems has proceeded rapidly and produced an expo-
nential growth in the efficiency and productivity of
laboratories. This has coincided with an exponentially
increasing demand for testing by the clinical commu-
nity. Increased demand is due to the interaction of a
number of different factors including increasing com-
plexity of the available medical treatments, a shift to
more sophisticated community-based care which
utilises diagnostics and an increasing number of older
patients with multiple comorbidities. It is interesting to
speculate whether the ready availability of testing has
also contributed to its increasing utilisation. 
Technological change has resulted in a number
of largely managerial challenges for the laboratory.
Increased automation has partially offset the shortage
of skilled laboratory staff but also led to a need to
reconfigure laboratories to exploit economies of
scale. The introduction of laboratory networks with
centralisation to produce a hub and spoke model has
been a response to this pressure. Such a model brings
its own complications with a need to have staff dis-
tributed according to demand and workflow plus the
need to maintain 24/7 provision of acute care across
the entire network. It also imposes logistics chal-
lenges with any need for sample movement and
tracking. The key to underpinning such a service is a
good and reliable, fully integrated, robust information
technology (IT) infrastructure. The lack of such an
infrastructure is a common problem as has recently
been highlighted.
Novel technologies capable of direct clinical
impact are also now present in the central laboratory.
Advanced automation of molecular diagnostics with
next-generation sequencing means that tests which
were previously labour intensive and expensive, such
as screening for familial hypercholesterolemia (FH)
are more available. The laboratory can embrace this
technology focusing it at the clinical problem of diag-
nosis in patients with hypercholesterolemia by provid-
ing sequencing of the four principal FH genes, but
combining this with scoring for polygenic hyperc-
holesterolemia (13). The routine use of tandem mass
spectrometry allows efficient measurement of
immunosuppressant drugs as well as steroid hormone
measurement but »traditional« laboratory questions
such as standardisation remain (14).
In addition to technological development within
the laboratory there has been innovation with the
development of methods of performing analyses at
the point of care, point of care testing (POCT).
Uptake and utilisation of these novel technologies has
been different in Europe and the United States due to
different regulatory environments. The use of point of
care, blood gas testing is standard in Europe, with
many traditional central laboratory tests required for
urgent care incorporated within blood gas analysers.
The role of laboratory is collaboration with the clini-
cian the supervision and quality assurance, which can
be facilitated by appropriate IT infrastructure.
Laboratory medicine may take the lead in intro-
ducing new tests. Cardiac biomarker measurement
has had a crucial role in defining diagnosis, manage-
ment strategies and latterly treatment options in
patients with ischaemic heart disease. The measure-
ment of aspartate transaminase was the first indepen-
dent biomarker that allowed a definitive diagnosis of
myocardial infarction (15, 16). The progressive evo-
lution of cardiac biomarker measurement ultimately
resulted in the introduction of troponin testing.
Measurement of cardiac troponin provides diagnostic
information but also serves as the key test to direct
the patient along therapeutic pathways. The laborato-
ry had a key role in introducing this test to clinicians.
The first major initiative which contributed to the
redefinition of myocardial infarction was a consensus
conference of clinical biochemists (17). 
To this day the laboratory provides the focus for
development of the application of troponin testing.
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Here, the particular expertise of the laboratory is
required. Although clinical guidelines are entirely
consistent in the recommendations for diagnostic
strategies using troponin in particular the adoption of
the 99th percentile (18), it has been found that these
recommendations have not been universally adopted
(19). It is important that laboratory medicine helps
with the implementation of such guidelines. 
One of the challenges of medical progress is a
tendency to retain previous testing strategies and not
remove obsolete tests from the clinical repertoire. A
good example is the introduction of the measurement
of cardiac troponin. It is only comparatively recently
that tests which have been superseded for the detec-
tion of myocardial injury, such as aspartate transami-
nase and lactate dehydrogenase or tests which are
methodologically inadequate, such as creatine kinase
isoenzyme MB measured by a immunoinhibition,
have been removed from cardiac panels (19–21).
They have often been retained despite specific guide-
line recommendations (22).
Service configuration
Laboratory medicine must be responsive to new
treatment strategies which utilise testing in novel
ways. Provision of testing may present interesting
logistic challenges requiring either reorganisation of
services or the implementation of novel technologies.
The use of selective catheterisation to localise
parathyroid tumours is an example where the ability
to measure parathormone effectively in real time is
required to support surgical exploration of the neck.
Similarly, the progressive increase in the amount of
cross sectional imaging (computed tomography and
magnetic resonance imaging) utilising contrast, has
required pre-imaging assessment of renal function.
Many patients arrive for their imaging without having
been pre-investigated. This problem can be dealt with
by the use of point of care creatinine measurement in
the imaging department. 
Introduction of rapid diagnostic strategies in
patients with chest pain initially utilised serial mea-
surements of creatine kinase (CK) and its MB isoen-
zyme (CK-MB) (23, 24). These could be provided by
dedicated stat instruments either in the laboratory or
in close proximity to the patient (POCT). The most
recent recommendations for cardiac troponin have
suggested measurement on admission and at 3 hours
(25). Current laboratory methodology can provide
this degree of analytical sensitivity and imprecision
but this does not match the turnaround time is
required by the clinician. Although POCT is the obvi-
ous answer, as yet it cannot match the analytical per-
formance goals (26). An understanding of the analyt-
ical performance of troponin testing will also inform
clinical colleagues as to what is the optimal decision-
making algorithm. Although rapid diagnosis with test-
ing on admission and one hour and calculation of a
delta has been endorsed within the most recent set of
guidelines (25), questions have been raised as to
whether routine analytical performance of even labo-
ratory troponin assays allows the proposed very small
delta changes in troponin to be precisely and accu-
rately measured (27).
Meeting future needs
Finally, there is the appearance of new diseases
and a need for a laboratory response. The recent
Ebola and Zika virus outbreaks highlighted a crucial
need for diagnostics but a lack of laboratory tests suit-
able both analytically and logistically suitable for the
clinical situation where the outbreaks occurred.
Although infectious diseases are the most spectacular
examples it must be remembered that as yet we do
not have good laboratory tests for the diagnosis of
acute cerebrovascular disease (brain attack) or for
what is now the largest single cause of death, demen-
tia. There is much yet to be done.
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